James M. Mason

Articles in Scholarly Journals [Incomplete List]

  1. Diagnostic and Prognostic Value of Plasma Tumor M2 Pyruvate Kinase in Periampullary Cancer
    Pancreas, vol. 34, no. 3, pp. 318–324, 2007
  2. Transcriptional Activity of the Telomeric Retrotransposon HeT-A in Drosophila melanogaster Is Stimulated as a Consequence of Subterminal Deficiencies at Homologous and Nonhomologous Telomeres
    Molecular and Cellular Biology, vol. 27, no. 13, pp. 4991–5001, 2007
  3. BMC Health Services Research, vol. 6, no. 1, p. 47, 2006
  4. The Generalisability of Pharmacoeconomic Studies
    PharmacoEconomics, vol. 24, no. 10, pp. 937–945, 2006
  5. Economic Analysis of a Telemedicine Intervention to Improve Glycemic Control in Patients with Diabetes Mellitus
    Disease Management & Health Outcomes, vol. 14, no. 6, pp. 377–385, 2006
  6. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials
    Journal of Hypertension, vol. 24, no. 2, p. 215???233, 2006
  7. Lifestyle interventions to reduce raised blood pressure
    Journal of Hypertension, vol. 24, no. 10, p. 2116???2117, 2006
  8. A new method of analysis enabled a better understanding of clinical practice guideline development processes
    Journal of Clinical Epidemiology, vol. 59, no. 11, pp. 1199–1206, 2006
  9. Effects of telomere length in Drosophila melanogaster on life span, fecundity, and fertility
    Chromosoma, vol. 116, no. 1, pp. 41–51, 2006
  10. Lifestyle interventions to prevent osteoporotic fractures: a systematic review
    Osteoporosis International, vol. 17, no. 1, pp. 20–28, 2005
  11. Managing dyspepsia without alarm signs in primary care: new national guidance for England and Wales
    Alimentary Pharmacology and Therapeutics, vol. 21, no. 9, pp. 1135–1143, 2005
  12. Review article: gastro-oesophageal reflux disease - the health economic implications
    Alimentary Pharmacology and Therapeutics, vol. 22, no. s1, pp. 20–31, 2005
  13. Specialist Nurse-Led Clinics to Improve Control of Hypertension and Hyperlipidemia in Diabetes: Economic analysis of the SPLINT trial
    Diabetes Care, vol. 28, no. 1, pp. 40–46, 2005
  14. Pro-Active Call Center Treatment Support (PACCTS) to Improve Glucose Control in Type 2 Diabetes: A randomized controlled trial
    Diabetes Care, vol. 28, no. 2, pp. 278–282, 2005
  15. Acceptability and Satisfaction With a Telecarer Approach to the Management of Type 2 Diabetes
    Diabetes Care, vol. 28, no. 2, pp. 283–289, 2005
  16. Two Distinct Domains in Drosophila melanogaster Telomeres
    Genetics, vol. 171, no. 4, pp. 1767–1777, 2005
  17. BMC Health Services Research, vol. 5, no. 1, p. 25, 2005
  18. Euchromatic and heterochromatic domains at Drosophila telomeres
    Biochemistry and Cell Biology, vol. 83, no. 4, pp. 477–485, 2005
  19. Retrotransposition-Competent Human LINE-1 Induces Apoptosis in Cancer Cells With Intact p53
    Journal of Biomedicine and Biotechnology, vol. 2004, no. 4, pp. 185–194, 2004
  20. A Deficiency Screen for Dominant Suppressors of Telomeric Silencing in Drosophila
    Genetics, vol. 168, no. 3, pp. 1353–1370, 2004
  21. Educational outreach in diabetes to encourage practice nurses to use primary care hypertension and hyperlipidaemia guidelines (EDEN): a randomized controlled trial
    Diabetic Medicine, vol. 21, no. 6, pp. 599–603, 2004
  22. Lifestyle interventions or drugs for patients with essential hypertension
    Journal of Hypertension, vol. 22, no. 11, pp. 2043–2048, 2004
  23. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment
    European Heart Journal, vol. 24, no. 5, pp. 464–474, 2003
  24. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis
    European Heart Journal, vol. 24, no. 5, pp. 442–463, 2003
  25. Genetica, vol. 117, no. 2/3, pp. 319–325, 2003
  26. Specialist Nurse-Led Intervention to Treat and Control Hypertension and Hyperlipidemia in Diabetes (SPLINT): A randomized controlled trial
    Diabetes Care, vol. 26, no. 8, pp. 2250–2255, 2003
  27. Evaluation of a complex intervention for changing professional behaviour: the Evidence Based Out Reach (EBOR) Trial
    Journal of Health Services Research and Policy, vol. 7, no. 4, pp. 230–238, 2002
  28. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial
    Alimentary Pharmacology and Therapeutics, vol. 16, no. 3, pp. 559–568, 2002
  29. The Costs of Making Practice More Cost-effective
    JAMA: The Journal of the American Medical Association, vol. 287, no. 13, pp. 1648–1650, 2002
  30. When Is It Cost-effective to Change the Behavior of Health Professionals?
    JAMA: The Journal of the American Medical Association, vol. 286, no. 23, pp. 2988–2992, 2001
  31. The use of primary, secondary, community and social care by families who frequently consult their general practitioner
    Health and Social Care in the Community, vol. 9, no. 6, pp. 375–382, 2001
  32. Psychiatric illness and mortality after hip fracture
    The Lancet, vol. 357, no. 9264, pp. 1264–1265, 2001
  33. Lefty Proteins Exhibit Unique Processing and Activate the MAPK Pathway
    Journal of Biological Chemistry, vol. 276, no. 24, pp. 21387–21396, 2001
  34. Impact of Effective Health Care bulletin on treatment of persistent glue ear in children: time series analysis
    BMJ, vol. 323, no. 7321, pp. 1096–1097, 2001
  35. Developing valid cost effectiveness guidelines: a methodological report from the North of England evidence based guideline development project
    Quality in Health Care, vol. 9, no. 2, pp. 127–132, 2000
  36. Complications of diabetes: screening for retinopathy and management of foot ulcers
    Quality in Health Care, vol. 9, no. 2, pp. 137–141, 2000
  37. Reverse transcriptase can stabilize or destabilize the genome
    Genome, vol. 43, no. 6, pp. 949–956, 2000
  38. Effect of population screening and treatment for on dyspepsia and quality of life in the community: a randomised controlled trial
    The Lancet, vol. 355, no. 9216, pp. 1665–1669, 2000
  39. Genetica, vol. 109, no. 1/2, pp. 61–70, 2000
  40. The Euro Heart Failure Survey of The EUROHEART Survey Programme A survey on the quality of care among patients with heart failure in Europe
    European Journal of Heart Failure, vol. 2, no. 2, pp. 123–132, 2000
  41. Hepatocyte Growth Factor Decreases Sensitivity to Chemotherapeutic Agents and Stimulates Cell Adhesion, Invasion, and Migration
    Biochemical and Biophysical Research Communications, vol. 274, no. 3, pp. 772–779, 2000
  42. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia
    BMJ, vol. 321, no. 7262, pp. 659–664, 2000
  43. Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction
    BMJ, vol. 321, no. 7269, pp. 1113–1116, 2000
  44. The Importance of Achieving Additional Drug Benefits at a Reasonable Cost
    PharmacoEconomics, vol. 17, no. 4, pp. 319–324, 2000
  45. Challenges to the Economic Evaluation of New Biotechnological Interventions in Healthcare
    PharmacoEconomics, vol. 16, no. 2, pp. 119–125, 1999
  46. The DiSC ASSAYA Cost-effective Guide to Treatment for Chronic Lymphocytic Leukemia?
    International Journal of Technology Assessment in Health Care, vol. 15, no. 1, pp. 173–184, 1999
  47. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. I: prevention
    Diabetic Medicine, vol. 16, no. 10, pp. 801–812, 1999
  48. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. II: treatment
    Diabetic Medicine, vol. 16, no. 11, pp. 889–909, 1999
  49. A Randomized Trial of Evidence-Based Outreach (EBOR) Rationale and Design
    Controlled Clinical Trials, vol. 20, no. 5, pp. 479–492, 1999
  50. A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines
    Health Policy, vol. 47, no. 1, pp. 37–52, 1999
  51. North of England evidence-based guideline development project: summary version of guidelines for the choice of antidepressants for depression in primary care
    Family Practice, vol. 16, no. 2, pp. 103–111, 1999
  52. Tissue engineering and gene therapy in facial plastic surgery
    Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 6, no. 4, pp. 226–231, 1998
  53. Directional gene silencing induced by a complex subtelomeric satellite from Drosophila
    Chromosoma, vol. 107, no. 5, pp. 311–320, 1998
  54. The Dilemma of New Drugs
    PharmacoEconomics, vol. 13, no. 6, pp. 653–657, 1998
  55. Chromosoma Focus
    Chromosoma, vol. 106, no. 2, pp. 63–69, 1997
  56. Biotechnology: a special case for health technology assessment?
    Health Policy, vol. 41, no. 1, pp. 73–81, 1997
  57. Optometrist screening for diabetic retinopathy: evidence and environment
    Ophthalmic and Physiological Optics, vol. 16, no. 4, pp. 274–285, 1996
  58. Meiotic recombination and germ cell aneuploidy
    Environmental and Molecular Mutagenesis, vol. 28, no. 3, pp. 192–210, 1996
  59. Molecular cloning of mei-41, a gene that influences both somatic and germline chromosome metabolism of Drosophila melanogaster
    MGG Molecular & General Genetics, vol. 246, no. 2, pp. 148–155, 1995
  60. DNA organization and polymorphism of a wild-type Drosophila telomere region
    Chromosoma, vol. 104, no. 4, pp. 229–241, 1995
  61. Reporting guidelines for economic studies
    Health Economics, vol. 4, no. 2, pp. 85–94, 1995
  62. The unusual telomeres of Drosophila
    Trends in Genetics, vol. 11, no. 2, pp. 58–62, 1995
  63. Cost-effectiveness league tables: think of the fans
    Health Policy, vol. 31, no. 3, pp. 231–238, 1995
  64. Purchasing and Public Health: The State of the Union
    Journal of Management in Medicine, vol. 8, no. 1, pp. 6–11, 1994
  65. Telomeric repeat sequences
    Chromosoma, vol. 103, no. 3, pp. 154–161, 1994
  66. Chemical mutagenesis testing inDrosophila. IX. Results of 50 coded compounds tested for the national toxicology program
    Environmental and Molecular Mutagenesis, vol. 23, no. 1, pp. 51–63, 1994
  67. Chemical mutagenesis testing inDrosophila. X. Results of 70 coded chemicals tested for the national toxicology-program
    Environmental and Molecular Mutagenesis, vol. 23, no. 3, pp. 208–227, 1994
  68. The genomic organization of HeT-A retroposons inDrosophila melanogaster
    Chromosoma, vol. 102, no. 5, pp. 297–305, 1993
  69. Cost-effectiveness league tables: More harm than good?
    Social Science & Medicine, vol. 37, no. 1, pp. 33–40, 1993
  70. Chemical mutagenesis testing inDrosophila: VIII. Reexamination of equivocai results
    Environmental and Molecular Mutagenesis, vol. 19, no. 3, pp. 227–234, 1992
  71. Aneuploidy in Drosophila, II. Further validation of the FIX and ZESTE genetic test systems employing female Drosophila melanogaster
    Mutation Research/Genetic Toxicology, vol. 259, no. 2, pp. 147–163, 1991
  72. Recovery and characterization of hybrid dysgenesis-induced mei-9 and mei-41 alleles of Drosophila melanogaster
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 229, no. 1, pp. 17–28, 1990
  73. Addition of telomere-associated HeT DNA sequences “heals” broken chromosome ends in Drosophila
    Cell, vol. 61, no. 4, pp. 663–673, 1990
  74. Aneuploidy in Drosophila, I. Genetic test systems in the female Drosophila melanogaster for the rapid detection of chemically induced chromosome gain and chromosome loss
    Mutation Research/Environmental Mutagenesis and Related Subjects, vol. 234, no. 5, pp. 319–326, 1990
  75. Chromosome Ends in Drosophila Without Telomeric DNA Sequences
    Proceedings of the National Academy of Sciences, vol. 87, no. 5, pp. 1758–1761, 1990
  76. Chemical mutagenesis testing inDrosophila. VI. Interlaboratory comparison of mutagenicity tests after treatment of larvae
    Environmental and Molecular Mutagenesis, vol. 14, no. 4, pp. 238–244, 1989
  77. Chemical mutagenesis testing inDrosophila. VII. Results of 22 coded compounds tested in larval feeding experiments
    Environmental and Molecular Mutagenesis, vol. 14, no. 4, pp. 245–251, 1989
  78. Genetic characterization of the mei-41 locus in Drosophila melanogaster
    MGG Molecular & General Genetics, vol. 215, no. 2, pp. 190–199, 1989
  79. Genotoxicity studies of methyl isocyanate in salmonella, drosophila, and cultured chinese hamster ovary cells
    Environmental Mutagenesis, vol. 9, no. 1, pp. 19–28, 1987
  80. A guide for performing germ cell mutagenesis assays using Drosophila melanogaster
    Mutation Research/Genetic Toxicology, vol. 189, no. 2, pp. 93–102, 1987
  81. Current status of aneuploidy testing in drosophila
    Mutation Research/Reviews in Genetic Toxicology, vol. 167, no. 1-2, pp. 71–87, 1986
  82. Chemical mutagenesis testing inDrosophila. III. Results of 48 coded compounds tested for the national toxicology program
    Environmental Mutagenesis, vol. 7, no. 3, pp. 325–348, 1985
  83. Chemical mutagenesis testing indrosophila. IV. Results of 45 coded compounds tested for the national toxicology program
    Environmental Mutagenesis, vol. 7, no. 3, pp. 349–367, 1985
  84. Genetic drift and seasonal variation in spontaneous mutation frequencies inDrosophila
    Environmental Mutagenesis, vol. 7, no. 5, pp. 663–676, 1985
  85. Chemical mutagenesis testing inDrosophila. V. Results of 53 coded compounds tested for the national toxicology program
    Environmental Mutagenesis, vol. 7, no. 5, pp. 677–702, 1985
  86. Chemical mutagenesis testing inDrosophila: I. Comparison of positive and negative control data for sex-linked recessive lethal mutations and reciprocal translocations in three laboratories
    Environmental Mutagenesis, vol. 6, no. 2, pp. 189–202, 1984
  87. mu-2: Mutator Gene in Drosophila That Potentiates the Induction of Terminal Deficiencies
    Proceedings of the National Academy of Sciences, vol. 81, no. 19, pp. 6090–6094, 1984
  88. Statistical analysis and sample-size determinations for mutagenicity experiments with binomial responses
    Environmental Mutagenesis, vol. 5, no. 5, pp. 705–716, 1983
  89. Genetic analysis of X-linked mutagen-sensitive mutants of Drosophila melanogaster
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 81, no. 3, pp. 329–343, 1981